Vitamin D analogues for secondary hyperparathyroidism

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 10, 2002, Pages 10-19

  Brown, Alex J ^a,b   Dusso, Adriana S ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Box 8126 ^*  (United States)

Author keywords

Calcium; Chronic renal failure; OCT; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D analogues

Indexed keywords

1,24 DIHYDROXYVITAMIN D2; 1,25 DIHYDROXYDIHYDROTACHYSTEROL; 1,25 DIHYDROXYERGOCALCIFEROL; 20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; 22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; DOXERCALCIFEROL; EB 1213; FALECALCITRIOL; GS 1725; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; UNCLASSIFIED DRUG; VITAMIN; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM ABSORPTION; CELL GROWTH; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; GENE EXPRESSION; GENE REPRESSION; HORMONE INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; HYPERPHOSPHATEMIA; NONHUMAN; OSTEOLYSIS; PARATHYROID CELL; PARATHYROID FUNCTION; PARATHYROID GLAND; PATHOGENESIS; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 0036411910     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_10.10     Document Type: Article

References (49)

1. 3 analogues. Chem Pharm Bull 1986; 34: 4410-4413
2. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-732
3. Naveh-Many T, Silver J. Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression. Endocrinology 1993; 133: 2724-2728
4. Brown AJ, Finch JL, Lopez-Hilker S et al. New active analogues of vitamin D with low calcemic activity. Kidney Int 1990; 29 [Suppl 29]: S22-S27
5. Hirata M, Katsumata K, Masaki T et al. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999; 56:2040-2047
6. Monier-Faugere MC, Geng Z, Friedler RM et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55:821-832
7. Tsukamoto Y, Hanaoka M, Matsuo T et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000;35:458-464
8. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-860
9. 2 (19-nor) on PTH and bone histomorphometry in uremic rats. J Am Soc Nephrol 2000; 11: 583A
10. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-1056
11. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30:105-112
12. CIP1/WAF1 and reducing the expression of transforming growth factor α (TGFα) expression. J Am Soc Nephrol 2000; 11: 574A
13. 2 (Paricalcitol) safety and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
14. 2. Am J Kidney Dis 1998; 32: S61-S66
15. Llach F, Yudd M, Paricalcitol in patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kid Dis 2001; 38: S45-S50
16. Martin KJ, Gonzalez E, Lindberg JS et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized trial. Am J Kidney Dis 2001; 38: S57-S63
17. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-323
18. 2 in suppressing secondary hyperparathyroidism in hemodialysis patients. Dialysis Transplant 1997; 26: 583-595
19. 2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 1998; 3: 68-72
20. Maung HM, Elangovan L, Frazao JM et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532-543
21. 3 in uremic patients on hemodialysis: preliminary report. Contrib Nephrol 1991; 90: 196 203
22. Akiba T, Marumo F, Owada A et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998; 32: 238-246
23. Fan SLS, Schroeder NJ, Calverley MJ et al. Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2). Nephol Dial Transplant 2000; 15:1943-1949
24. Hruby M, Urena P, Mannstadt M et al. Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11: 1781-1786
25. Dusso AS, Negrea L, Gunawardhana S et al. On the mechanisms for the selective action of vitamin D analogues. Endocrinology 1991; 128: 1687-1692
26. 3. J Nutr Sci Vitaminol 1989; 35:529-533
27. Brown AJ, Finch J, Grieff M et al. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 1993; 133: 1158-1164
28. 3, in rats. J Biochem 1994; 115:373-380
29. 3 derivatives, 22-oxa-1 alpha-25-dihydroxyvitamin D3 (OCT) and 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3 (ED-71), on bone metabolism in organ culture. Bone 1993; 14:47-51
30. Takeyama K, Masuhiro Y, Fuse H et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analogue. Mol Cell Biol 1999; 19: 1049-1055
31. Dusso AS, Negrea L, Finch J et al. The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 1992; 130: 3129-3134
32. Grieff M, Dusso A, Mori T et al. 22-Oxacalcitriol suppresses 25-hydroxycholecalciferol-1 alpha-hydroxylase in rat kidney. Biochem Biophys Res Commun 1992; 185: 191-196
33. Brown AJ, Berkoben M, Ritter C et al. Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells. Biochem Biophys Res Commun 1992; 189:759-764
34. Kamimura S, Gallieni M, Kubodera N et al. Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes. Endocrinology, 1993; 133:2719-2723
35. Bikle DD, Abe-Hashimoto J, Su MJ et al. 22-Oxa-calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism. J Invest Dermatol 1995; 105: 693-698
36. 2 decreases with duration of treatment. J Am Soc Nephrol 2000; 11: 2088-2094
37. Takahashi N, Yamana H, Yoshiki S et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988; 122: 1373-1382
38. 2, a vitamin D analogues with reduced bone resorbing activity in vitro. J Am Soc Nephrol 2000; 11: 1857-1864
39. 2 on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephol 2001; 12: 1468-1474
40. 3 in the rat. Proc Soc Exp Biol Med 1985; 178: 432-436
41. DeLuca HF, Sicinski RR, Tanaka Y et al. Biological activity of 1,25-dihydroxyvitamin D2 and 24-epi-1,25-dihydroxyvitamin D2. Am J Physiol 1988; 254: E402-E406
42. Reinhardt TA, Ramberg CF, Horst RL. Comparison of receptor binding, biological activity, and in vivo tracer kinetics for 1,25-dihydroxyvitamin D3, 1,25-dihydroxyvitamin D2, and its 24 epimer. Arch Biochent Biophys 1989; 273: 64-71
43. 2 detectable in human serum. J Clin Endocrinol Metab 1998; 83: 2156-2166
44. 3 in the bones of rats dosed with tritium-labeled compounds. Steroids 1998; 63: 505-510
45. 3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. Xenobiotica 1999; 29: 603-613
46. 3. Biochem J 1993; 295: 509-516
47. 3. Biochem Pharmacol 1993; 45: 2331-2336
48. 3 in cultured neonatal mouse calvaria. Res Commun Mol Pathol Pharmacol 1994; 86: 183-193
49. 3. Arch Biochem Biophys 1984; 229: 348-354